Abstract
The humanized anti-CD52 monoclonal antibody, alemtuzumab (or Campath-1H), has been shown to potently deplete lymphocytes in human patients. It has been used to successfully treat graft versus host disease and chronic lymphocytic leukemia (CLL). CD52 is expressed on normal lymphocytes, monocytes, and some dendritic cell subsets. However, normal Langerhans cells (LC's) in the skin do not bind alemtuzumab. We sought to determine whether the pathologic LC's of Langerhans cell histiocytosis (LCH) express CD52 and thus could be targeted by this antibody. Immunohistochemistry was performed on both frozen and fixed/paraffin-embedded tissue specimens using either Campath-1G (the parental rat isotype) or Campath-1H (the humanized version of Campath in clinical use). Both Campath-1H and Campath-1G were found to bind to the pathologic LC's in LCH, but not the normal LC's of skin. Specific staining was demonstrated in all (13 of 13) LCH specimens examined, though staining was somewhat variable among specimens, and tended to be weaker in paraffin-embedded specimens. Expression of CD52 by the pathologic LC's seen in LCH suggests that alemtuzumab may represent a new, targeted therapy for this disease. Such therapy is particularly needed for pa...Continue Reading
References
Jul 1, 1991·European Journal of Immunology·M Q XiaH Waldmann
Mar 1, 1990·Tissue Antigens·G HaleH Waldmann
Aug 1, 1993·The Biochemical Journal·M Q XiaH Waldmann
Oct 1, 1994·The Journal of Pathology·J F EmileN Brousse
Apr 1, 1994·Journal of Clinical Pathology·J R SalisburyA B Nethersell
Apr 30, 1998·Hematology/oncology Clinics of North America·C L Willman, K L McClain
Feb 27, 2001·Blood·F GeissmannN Brousse
Mar 16, 2002·Blood·Phennapha KlangsinsirikulNigel H Russell
May 3, 2002·Blood·Michael J KeatingKanti R Rai
Jul 20, 2002·Blood·Jeanette LundinAnders Osterborg
Aug 13, 2002·Cytotherapy·P D KottaridisS MacKinnon
Sep 11, 2002·American Journal of Clinical Pathology·Geraldine S PinkusJack L Pinkus
Oct 12, 2002·Medical and Pediatric Oncology·Milen MinkovUNKNOWN DAL-HX Study Group
Oct 24, 2002·Blood·Gudrun RatzingerJames W Young
Mar 19, 2003·Blood·Mark D FlemingBarrett J Rollins
Apr 17, 2003·Trends in Immunology·Jon D LamanR Maarten Egeler
May 14, 2003·The Journal of Experimental Medicine·Nicola E AnnelsR Maarten Egeler
Citations
Oct 10, 2006·Skeletal Radiology·Kevin Bradford HooverHenry Mankin
Nov 19, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Joan Manel Gasent BlesaCarlos Rodríguez-Galindo
Mar 1, 2011·Paediatric Drugs·Milen Minkov
Aug 21, 2014·American Journal of Otolaryngology·S M XieJ H Ren
Nov 2, 2005·Expert Opinion on Pharmacotherapy·Kenneth L McClain
Nov 23, 2006·Cancer Investigation·Farhad Ravandi, Susan O'brien
Jul 3, 2015·Experimental and Therapeutic Medicine·Lintao BiZhenxing Zhu
Mar 22, 2006·European Journal of Haematology·Marcus Stockschlaeder, Christoph Sucker
Dec 16, 2011·Cancer·Neerav ShuklaPeter Steinherz
Jul 30, 2011·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·R J LeeA G Speer
Sep 1, 2012·British Journal of Haematology·Gitanjali I BechanRobert J Arceci
Dec 10, 2013·Experimental Dermatology·Rafiq AndaniKiarash Khosrotehrani
Nov 26, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra FilipovichAlexei Grom
May 10, 2016·Experimental Hematology·Anna Rita Migliaccio
Jun 7, 2005·Bone Marrow Transplantation·M SteinerH Gadner
Dec 9, 2010·Rare Tumors·Valérie FaillaArjen F Nikkels
Feb 21, 2006·Bone Marrow Transplantation·W IngramG Mufti
Nov 25, 2004·Hematology·Kenneth L McClainSteven H Swerdlow
Jan 18, 2014·The Oncologist·Francesca M RizzoFranco Silvestris